Kornimate/medical-research-clean huggingface dataset:
total laparoscopic hysterectomy versus total abdominal hysterectomy in women with endometrial neoplasia

Conditions: Hysterectomy; Laparoscopy

Summary: the aim of this study is to compare operative time between total laparoscopy hysterectomy with bilateral salpingoophrectomy (tlh+bso) versus total abdominal hysterectomy and bilateral salpingooophorectomy (tah+bso) in women with uterine neoplasia.

research questions: is total laparoscopic hysterectomy associated with similar operative operative time as total abdominal hysterectomy and bilateral salpingoophrectomy in women with uterine neoplasia? research hypothesis: in women with uterine neoplasia tlh with bso may be similar to tah with bso as regard operative time.

Eligibility criteria:
inclusion criteria: the presence of perimenopausal bleeding * early stage endometrial carcinoma. * endometrial hyperplasia with/without atypia. exclusion criteria: * obese patients i.e., bmi\< 29 k.g/m2. * patients unfit for laparoscopy as patients with cardio-pulmonary compromise. * presence of adnexal mass. * end stage endometrial carcinoma stage 3 \& 4.
vericiguat for heart failure with reduced ejection fraction after myocardial infarction

Conditions: HFrEF - Heart Failure With Reduced Ejection Fraction; Myocardial Infarction (MI)

Summary: the effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. this project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of qilu hospital of shandong university will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. after 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. the results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.


Eligibility criteria:
inclusion criteria: 1. the history of acute myocardial infarction exceeds 3 months; 2. symptoms and signs of heart failure have been stable for more than one month; 3. 18 years old or more; 4. nyha cardiac function classified as grade ii\~iv; 5. lvef≤40%； 6. nt-probnp≥450pg/ml； 7. all subjects or their guardians must sign the subject consent before entering the trial. exclusion criteria: 1. patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor; 2. mechanical complications of myocardial infarction; 3. unable to obtain primary outcome data.

Keywords: hfref myocardial infarction vericiguat
prevention of hamstring injuries in football players.

Conditions: Hamstring Injuries

Summary: introduction: the prevalence of hamstring injuries in football is high, causing an increase in the number of casualties and a high socio-economic cost. currently there are different treatment protocols for this muscle group, but there are often no comparisons of different types of passive, active and combined therapies, and their potential efficacy, in professional football players. objectives: to compare the efficacy of three different interventions; passive manual therapy, active therapy based on therapeutic exercise and combined therapy, in relation to hamstring injuries in professional football players. methodology: a simple randomised clinical trial (rct) was conducted (nct04935398). after applying the selection criteria, a sample of 66 professional football players was obtained. they were divided into 3 intervention groups (a, b and c) with 22 participants in each group and were given passive manual therapy, active therapy (exercise) and combined therapy (sum of the above). the corresponding tests and questionnaires were evaluated to obtain data on hamstring flexibility and hip range of movement at three time periods: pre, post and post2.


Eligibility criteria:
inclusion criteria: * professional football athletes. * between 18-40 years of age. * male gender. * active in competitive season. exclusion criteria: * neurological signs. * inability to follow the evaluator's instructions. * physical activity of less than 2 hours per week. * serious lower limb injury during the study period.

Keywords: physiotherapies techniques range of motion hamstring muscles prevention and control muscuoeskeletal manipulations.
hämeenlinna metabolic syndrome research program: surrogate indicators for atherosclerosis

Conditions: Metabolic Syndrome; Coronary Heart Disease

Summary: mechanisms that link metabolic syndrome to atherosclerosis are incompletely understood. as a part of hämeenlinna metabolic syndrome research program (hms) surrogate indicators for atherosclerosis are studied in 120 men with metabolic syndrome, 120 men with coronary heart disease and 80 physically active controls and in different settings.

accumulation of oxidized low-density lipoproteins (ldl) in the intimae of arteries together with risk factors known to enhance atherosclerosis, damage the endothelium of the arterial wall. dysfunction of the endothelium leads into loss of elasticity of the artery. surrogate indicators of atherosclerosis might be seen already in the early phase of otherwise subclinical arterial disease. in this study, we investigate calculated risk of the subjects (score, finrisk, framingham score), platelet function and surrogate indicators for atherosclerosis like erectile dysfunction, plasma levels of oxidized ldl, arterial elasticity and biochemical markers for endothelial damage and dysfunction in different settings (case-only and case-control).

Eligibility criteria:
inclusion criteria: group 1: metabolic syndrome * 120 finnish men with metabolic syndrome (mets) defined according to national cholesterol education program (ncep) adult treatment panel iii * mets diagnosed in routine health examination and laboratory tests * age: 30 to 65 years group 2: coronary heart disease (chd) * 120 finnish men with angiographically proven chd * age: 30 to 65 years group 3: control * 80 finnish men * exercising physically more than three times a week and more than 30 minutes per exercise on regular basis * never been studied or treated because of cardiovascular disease * age: 30 to 65 years

Keywords: metabolic syndrome coronary heart disease erectile dysfunction arterial elasticity oxidized low density lipoprotein cardiovascular diseases risk assessment endothelial dysfunction diabetes mellitus surrogate markers risk factors
a swedish questionnaire study to investigate the perception of menstrual bleedings

Conditions: Menorrhagia

Summary: this field based, questionnaire study will document observational data on womens perception of menstrual bleeding in a cross-section of women in sweden. each subject will complete the questionnaire at one occasion.


Eligibility criteria:
inclusion criteria: * all women 40-45 years available in the web-panel of sifo * completion of the web-based questionnaire exclusion criteria: * none

Keywords: menorrhagia heavy menstrual bleeding uterine hemorrhage menstruation disturbancies
the effect of helfer skin tap technique on pain, fear, and anxiety in children undergoing intramuscular injection

Conditions: Pain, Acute; Fear Anxiety; Child, Only; Injection Site

Summary: the aim of this study was to examine the effect of the helfer skin tapping technique on pain, fear, and anxiety in children who received intramuscular injections. the research hypotheses are as follows: h0: there is no significant difference between the intervention group and the the control group in the mean score of the "wong-baker faces pain rating scale", "child fear scale", and "child anxiety scale-state" during and after the helfer skin tapping technique. h1: during and after the helfer skin tapping technique, the mean score of the "wong-baker faces pain rating scale", "child fear scale", and "child anxiety scale-state" is significantly lower in the intervention group compared to the control group.

in this study, there will be two groups as the intervention (who will receive an intramuscular injection with the helfer skin tapping technique) and the control group (who will receive an intramuscular injection with routine technique). a power analysis was performed based on the number of children in both groups, based on another study using the scales to be used in the research. according to the calculations made in the g-power 3.1 demo package program, when the effect size was accepted as 0.8, it was seen that at least 32 cases in each group would be sufficient for 80% power. children who meet the research criteria will be randomly assigned to the intervention and control groups via http://www.randomize.org/ by assigning a number to the order of arrival at the hospital. the intramuscular injection will be applied to both the intervention and control groups. the children in the intervention group will receive an intramuscular injection with the helfer skin tapping technique and the control group will receive an intramuscular injection with routine technique in the pediatric emergency service. a researcher and a nurse were employed for the intramuscular injection both for the intervention and control groups. a pediatric nurse performed the intramuscular injection for all children and the other researcher helped the children to assess their pain, fear, and anxiety level. pain, fear, and anxiety in children were evaluated by the children and their parents before, during, 5 minute after the procedure. the intramuscular injection will be performed by the same nurse both in the intervention and control groups.

Eligibility criteria:
inclusion criteria: * the child is between the ages of 4-10 * the child's application to the pediatric emergency unit * parent and child agreeing to participate in the project * absence of speech and visual impairment of the child and his parents exclusion criteria: * the child is not between the ages of 4-10 * the child's application to another department except for the pediatric emergency unit * parent and child not agreeing to participate in the project * having speech and visual impairment of the child and his parents
immunologic control of drug resistant hiv

Conditions: HIV Infections

Summary: drug resistant hiv strains often develop in patients who have taken anti-hiv drugs for an extended time. however, these drug resistant hiv strains do not always cause an increase in the level of hiv in the blood. this study will explore why some patients with drug resistant virus continue to have low viral loads.

despite the emergence of high level drug resistance in hiv-infected patients on stable antiretroviral therapy, plasma hiv rna levels generally remain below the pretherapy viral load "set-point". the virologic and immunologic determinants of this lower steady state level of viremia have not been defined. preliminary data indicate that: 1) drug resistant variants have reduced replicative capacity and pathogenic potential; 2) drug resistant viremia is associated with reduced t cell activation and turnover compared to wild-type viremia; and 3) patients with low level drug resistant viremia often have hiv-specific cd4 cells that are absent in patients with higher levels of viremia. this study will investigate whether the emergence of a poorly fit, drug resistant variant results in the generation of an effective hiv-specific cd4 cell response and if this response contributes to the establishment of a lower steady state level of viremia. participants in this study will be followed for 2 years or until antiretroviral therapy is modified or discontinued. study visits will occur every 2 months, for a total of 14 visits. study visits will include a patient interview and blood tests to measure the breadth and magnitude of the hiv-specific cd4 and cd8 cell responses as a function of viral load, viral replicative capacity, drug resistance phenotype, t cell turnover, and thymic function.

Eligibility criteria:
inclusion criteria: * hiv-infected for at least 6 months prior to study entry * documented pretherapy or off-therapy viral load of more than 10,000 copies/ml on at least 2 occasions or more than 20,000 copies/ml on at least 1 occasion * at least a 70% reduction in plasma hiv rna levels from pretherapy baseline * stable highly active antiretroviral therapy (haart) regimen for at least 4 months prior to study entry * hiv viral load of 200 to 10,000 copies/ml for 3 months prior to study entry * cd4 count greater than 100 cells/mm3 and a nadir cd4 count less than 500 cells/mm3 * virologic failure as defined by dhhs guidelines on at least one haart regimen prior to the study entry haart regimen * documented adherence to antiretroviral therapy * two major resistance mutations to at least two antiretroviral drug classes exclusion criteria: * significant toxicity on current haart regimen

Keywords: treatment experienced drug resistance
real-world study on adjuvant octreotide therapy in pnets

Conditions: Pancreatic Neuroendocrine Tumor G2

Summary: adjuvant therapy in pancreatic neuroendocrine tumors (pnets) after radical resection lacks evidence-based data and is controversial. real-world data were clustered to validate whether the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence risk g2 pnet patients.

adjuvant therapy for pnets was proposed as an unmet clinical need by the european neuroendocrine tumor society group in 2016.1the clinical practice guidelines for pnets in china recommended initiation of clinical trials to investigate the role of adjuvant therapy for patients with a high-risk of recurrence. to address this unmet clinical need, the investigators initiated this real-world study. the aim of the current study was to assess the impact of octreotide lar as an adjuvant therapy in reducing recurrence and prolonging survival in chinese non-metastatic pnets patients at risk for recurrence.

Eligibility criteria:
inclusion criteria: * pnets lesions pathologically classified as who grade 2 * complete surgical resection (r0 or r1 was achieved) * adjuvant treatment was performed within 12 weeks after surgery exclusion criteria: * stage iv * other oncological history * previous antineoplastic systemic therapy * lack of information/details on recurrence or death.
safety and efficacy of qax576 in adults with moderate persistent allergic asthma

Conditions: Asthma

Summary: this study will evaluate the safety and efficacy of qax576 against asthma attacks in adults with moderate persistent allergic asthma


Eligibility criteria:
inclusion criteria: * history of asthma attacks * taking inhaled corticosteroids * non-smoking exclusion criteria: * women of child-bearing potential * history of respiratory disease other than asthma * history of severe allergy to food or drugs * previous use of monoclonal antibodies * very low or high body weight other protocol-defined inclusion/exclusion criteria may apply.

Keywords: asthma, interleukin-13
a clinical trial to evaluate the efficacy and safety of choline alfoscerate in vascular cognitive impairment patients

Conditions: Vascular Cognitive Impairment

Summary: this is a multi-center, randomized, double-blind, placebo-controlled, phase iv trial to evaluate the efficacy and safety of choline alfoscerate compared to placebo in mild cognitive impairment patients with cerebrovascular disease

subject will be randomised in a 1:1 ratio to receive either choline alfoscerate or it's placebo. investigational product(ip, choline alfoscerate or it's placebo) will be administered 3 times a day per oral during the treatment

Eligibility criteria:
inclusion criteria: * age ≥ 50 years * patients with vascular cognitive impairment according to modified fazekas scale grade 2\~3 and/or more than 3 of lacunar infarction in supratentorial * patients with clinical deterioration rating(cdr) score of 0.5 * patients with korean-montreal cognitive assessment (k-moca) score of 23 or less * walk or move using walking aids (i.e., walkers, walking sticks or wheelchairs) * written informed consent exclusion criteria: * clinical diagnosis of dementia (including secondary dementia due to alzheimer's disease, vascular dementia, infections of the central nervous system (e.g., hiv, syphilis), creutzfeld-jacob disease, pixie disease, huntington's disease, parkinson's disease, etc.) * medication of dementia within the past 3 months. (e.g., donepezil, galantamine, rivastigmine, memantine) * medication of brain functional improvement medication within the past 6 weeks. (e.g., citicoline, oxiracetam, piracetam, choline alfoscerate, nicergoline, nimodipine, ginko-biloba, acetyl-l carnitine) * no studies (no regular school entrance), illiteracy * stroke within the past 3 months * abnormal results from vitamin b12, thyroid stimulated hormone test (tsh), hiv-ab, and vdrl test contribute to or contribute to cognitive impairment of the subject * serious mental disorders such as severe depression, schizophrenia, alcoholism, drug dependence, etc. * severe cardiovascular disease such as myocardial infarction, unstable angina or heart failure within the past 6 months

Keywords: vascular cognitive impairment choline alfoscerate
bay38-9456 - pivotal trial for diabetes patient

Conditions: Erectile Dysfunction; Diabetes Mellitus

Summary: the superiority of bay 38-9456 10 mg and 20 mg regimens to placebo, and of 20 mg to 10 mg was confirmed in patients with diabetes mellitus suffering from erectile dysfunction. there was no large difference in incidence rate of drug-related adverse events between 10 mg and 20 mg regimens. overall the tolerability was considered good with both regimens.


Eligibility criteria:
inclusion criteria: * male with erectile dysfunction for more than 3 years according to the national institutes of health (nih) consensus statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance) * diabetes for more than 3 years exclusion criteria: * following to the labeling of japanese package insert for vardenafil 5/10 mg, except for the highest dose * spinal cord injury * history of surgical prostatectomy (excluding turp) * patients with an hba1c \> 12% at visit 1 * use of nitrates * use of potent cyp3a4 inhibitors * severe liver disease * presence of peyronie's disease

Keywords: vardenafil pde5 inhibitor erectile dysfunction diabetes mellitus sexual dysfunction
brain metabolism observed at 7 tesla

Conditions: Glut1 Deficiency Syndrome 1; Glucose Metabolism Disorders; Epilepsy; Glut1 Deficiency Syndrome 1, Autosomal Recessive; Glucose Transporter Type 1 Deficiency Syndrome; Glucose Transporter Protein Type 1 Deficiency Syndrome; Glucose Transport Defect

Summary: the goal is to develop methodology to monitor flux in the citric acid cycle in brain via 13c nuclear magnetic resonance (nmr) spectroscopy at 7 tesla.

the goal is to establish a protocol to 13c-label (from 13c-glucose) several physiological molecules: glucose, lactate, pyruvate and derived compounds. all of these molecules can undergo oxidation in the citric acid cycle. the intent is to study the 13c labeling pattern of these molecules in control and g1d subjects to determine if downstream products (such as 13c bicarbonate or 13c glutamate) due to oxidation in the mitochondria can be detected in brain or in blood by nmr analysis. while inside the instrument, the subjects may also undergo a 7t mr exam to correlate spectroscopy with brain structure.

Eligibility criteria:
inclusion criteria: 1. adolescents and adults with previously documented diagnosis of glut1 deficiency with diagnosis genetically confirmed or confirmed by pet scan of the brain. 2. ages 16 to 65 3. persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included. exclusion criteria: 1. people or patients with uncontrolled seizure disorder, defined as grand mal (not absence) seizure in the preceding 3 months. 2. pregnant females will be excluded. a serum or urine pregnancy test will be administered to all females of child bearing potential within 24 hours of administration of the tracer and mri scan. the pregnancy test will be communicated in person by the study pi. positive results in subjects 17 years old or younger will be disclosed to parent/guardian only. 3. subjects with typical implanted orthopedic metal in bone may be considered for inclusion in a 7t scan providing the implant is not within the volume of the radio frequency coil. the pi and the airc medical director will discuss each case and determine eligibility. 4. persons with icd, pacemakers, neurostimulators and other such devices will be excluded. 5. persons with claustrophobia are excluded. 6. persons with questionable ferrous implants, bullets, bb's, and shrapnel will be excluded. 7. subjects who are not fluent in english will be excluded because immediate cooperation and the ability to respond to instructions from the investigators are necessary.
randomized one-center controlled trial on a comprehensive nutritional intervention for children with cerebral palsy and asd

Conditions: Nutrition Disorder, Child

Summary: the study is a prospective, single-center, randomized controlled trial that will be conducted at the medical university of varna. this setting offers access to a wealth of clinical expertise in managing cp and asd and a rich tradition of conducting robust nutritional interventions.


Eligibility criteria:
inclusion criteria: * a formal diagnosis made by a qualified neurologist. the diagnosis can span across the different types of cp and asd. * expressed willingness to participate in the study. * availability for the entire duration of the study. exclusion criteria: * children with acute medical conditions or comorbidities that may significantly disrupt study assessments. * any severe infections within the last 10 days prior to the study. * presence of genetic syndromes that could influence nutritional status, e.g., silver russel syndrome or down syndrome. * parents with cognitive impairments, which might pose challenges in their participation during assessments/intervention. * children who have been part of any major dietary or nutritional interventions in the last three months.